The information in this announcement is NOT for publication OR
distribution in or into the United States of America, Australia, Canada
or any jurisdiction in which such distribution or publication could be
Biotechnologies AG ("Elanix"; "the company"), a developer of tissue
regeneration products and specialty cosmetics in the field of
dermatology and gynecology, announced today the completion of a capital
increase approved by the General Shareholder Assembly ("GSM”) on 24
August 2017. A total of 300,019 shares were placed at a subscription
price of EUR 3.75 resulting in gross proceeds of EUR 1.125 million. As a
result of the cash capital increase, the share capital of Elanix will
increase from EUR 6,799,200 to EUR 7,099,219.
Elanix will use the gross proceeds to:
Launch SKINrepair®, a dermatological cream that contains a
proprietary Cell Free Protein Complex (CFPC®) of various
proteins, such as collagen and fibronectin in the first half 2018.
Advance development of FirstCover, a bioresorbable and bioactive skin
dressing derived from progenitor skin fibroblasts to provide
protection and accelerated healing for burns, trauma and plastic
surgery, through regulatory approval as medical device and to market
Concurrent with the capital raise, Elanix has signed a term sheet
providing access to a financing facility with a leading istitutional
investor of up to EUR 11 million over 3 years.
"This fundraising provides Elanix with the immediate capital to deliver
on several product development milestones as well as sales and marketing
activities. The launch of SKINrepair during the first half of 2018 is a
key component of our commercialization strategy that will supplement the
growing revenue stream provided by GYNrepair® and Cells as a
Service. Development of FirstCover remains on track, with launch of the
initial CE Marked version planned for 2020,” said Tomas J. Svoboda, CEO
of Elanix Biotechnologies AG. "With the current market volatility, we
decided to pursue a financing proposal from a U.S. based fund, which
provides access to additional funds, to reach significant future
milestones over the next three years.”
Elanix develops and commercializes tissue regeneration products
for acute wound care, dermatological and gynecological applications, and
provides services in cell technologies. The company was founded in 2012
as a spin-out from the University Hospital of Lausanne (CHUV),
Switzerland, to commercialize a patented human progenitor cell
technology. Progenitor cells are fully differentiated yet
immunologically neutral cells that are very potent inducers of tissue
growth and healing. Elanix owns GMP certified Master and Working human
cell banks with vast quantities of cells.
Elanix has registered headquarters in Berlin, Germany, with offices in
Wiesbaden, Germany and Nyon, Switzerland. It is listed in the Regulated
Market on the Frankfurt Stock Exchange under the symbol ELN.F. For more
information and updates, visit www.elanixbiotechnologies.com.
This publication may contain certain forward-looking statements
regarding the Company and its business activities. Such statements may
involve certain risks, uncertainties and other factors which can lead to
the results, financial situation, performance and success of the Company
differing significantly in reality from what is expressed or implied by
such statements. The reader should therefore not place undue trust in
these statements, especially in connection with contracts and investment
decisions. The Company does not accept any obligation to update such
This communication may not be published or distributed in the United
States of America (including its territories and possessions), Canada,
Japan or Australia or in any other countries in which such publication
and distribution might be illegal. The distribution of this publication
may be subject to legal restrictions in some countries; anyone in
possession of this document or of the information referred to in it
should obtain information regarding such restrictions and adhere to
them. Non-adherence to such restrictions may constitute a breach of
capital market law in such countries.
This communication is neither an offer nor an invitation to subscribe
for or purchase shares of Elanix Biotechnologies AG in the United States
of America, Germany or any other country. Neither does this
communication constitute a prospectus under Directive 2003/71/EC of the
European Parliament and Council dated 4 November 2003 as amended (the
"Prospectus Directive"). The public offering in Germany is carried out
solely by means of and based on the share prospectus approved by the
Federal Supervisory Financial Authority (BaFin). This share prospectus
is published on the Elanix Biotechnologies AG website (https://elanixbiotechnologies.com/investor-relations/).
Any investment decision relating to Elanix Biotechnologies AG
subscription rights or shares should be made based on the prospectus.
Neither this publication nor its content may be used as a basis for an
offer in any country. The shares referred to above may be neither sold
nor offered in the United States of America insofar has no registration
has been undertaken or insofar as no exception from the registration
requirement applies under the United States Securities Act of 1933 as
last amended ("Securities Act"). Elanix Biotechnologies AG shares are
not and will not be registered according to the Securities Act.
This communication does not constitute a recommendation relating to the
placement of the shares described in this notice. Investors should
consult a professional advisor in determining the suitability of the
offer to the individual concerned.
In the United Kingdom, this publication is only intended for (i)
professional investors who fall under Article 19(5) of the Financial
Services and Markets Act 2000 (Financial Promotion) Order 2005 as
amended (hereinafter referred to as "Order") or (ii) persons who fall
under Article 49(2) (a) to (d) of the Order (high net worth companies,
private companies, etc.) (such persons are referred to collectively
hereinafter as "Relevant Persons"). Persons other than Relevant Persons
may not refer to this publication or rely on it. Any investment or
potential investment referred to in this publication is solely open to
Relevant Persons and is only entered into by Relevant Persons.
In member states of the European Economic Area which have implemented
the Prospectus Directive (the "Relevant Member States"), this
publication and any subsequent offer is aimed solely at "qualified
investors" as defined by the Prospectus Directive. For these purposes,
"Prospectus Directive" refers to Directive 2003/71/EC (including all
amendments, in particular Directive 2010/73/EU) and includes all
relevant implementation measures in the Relevant Member States.
No measures have been taken that would allow the shares to be offered or
purchased or this publication to be distributed in countries in which
this is not permitted. Anyone coming into possession of this publication
must obtain information regarding any restrictions themselves and
observe these accordingly.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180214005673/en/